<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148640</url>
  </required_header>
  <id_info>
    <org_study_id>DIA2014-01</org_study_id>
    <secondary_id>2014-002056-40</secondary_id>
    <nct_id>NCT02148640</nct_id>
  </id_info>
  <brief_title>The NOR-SWITCH Study</brief_title>
  <acronym>NOR-SWITCH</acronym>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diakonhjemmet Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South-Eastern Norway Regional Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Diakonhjemmet Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of switching from Remicade to
      the biosimilar treatment Remsima in patients with rheumatoid arthritis, spondyloarthritis,
      psoriatic arthritis, ulcerative colitis, Crohn's disease and chronic plaque psoriasis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of disease worsening</measure>
    <time_frame>52 weeks</time_frame>
    <description>A disease worsening in RA and PsA is defined as an increase in DAS28 of ≥ 1.2 from randomization and a minimum DAS score of 3.2.
A disease worsening in AS/SpA is defined as an increase in ASDAS of ≥1.1 from randomization and a minimum ASDAS of 2.1.
A disease worsening in ulcerative colitis is defined as an increase in Partial Mayo score of ≥ 3 points from randomization and a minimum partial Mayo score of ≥ 5 points.
A disease worsening in Crohn's disease is defined as an increase in HBI of ≥ 4 points from randomization and a minimum HBI score of 7 points.
A disease worsening in psoriasis is defined as an increase in PASI of ≥ 3 points from randomization and a minimum PASI score of 5.
If a patient does not fulfill the formal definition, but experiences a clinically significant worsening according to both the investigator and patient and which leads to a major change in treatment this should be considered as a disease worsening but recorded separately in the CRF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to disease worsening</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of study drug discontinuation</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to study drug discontinuation</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's global assessment of disease activity</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physicians's global assessment of disease activity</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation laboratory parameters</measure>
    <time_frame>52 weeks</time_frame>
    <description>ESR and CRP for all patients, Calprotectin for UC and CD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission status according to DAS28</measure>
    <time_frame>52 weeks</time_frame>
    <description>For RA and PsA patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity according to DAS28</measure>
    <time_frame>52 weeks</time_frame>
    <description>For RA and PsA patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission status according to CDAI</measure>
    <time_frame>52 weeks</time_frame>
    <description>For RA and PsA patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity according to CDAI</measure>
    <time_frame>52 weeks</time_frame>
    <description>For RA and PsA patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission status according to SDAI</measure>
    <time_frame>52 weeks</time_frame>
    <description>For RA and PsA patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity according to SDAI</measure>
    <time_frame>52 weeks</time_frame>
    <description>For RA and PsA patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission status according to ACR/EULAR</measure>
    <time_frame>52 weeks</time_frame>
    <description>For RA and PsA patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity according to ACR/EULAR</measure>
    <time_frame>52 weeks</time_frame>
    <description>For RA and PsA patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission status according to ASDAS</measure>
    <time_frame>52 weeks</time_frame>
    <description>For SpA patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity according to ASDAS</measure>
    <time_frame>52 weeks</time_frame>
    <description>For SpA patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission status according to Partial Mayo Score</measure>
    <time_frame>52 weeks</time_frame>
    <description>For UC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity according to Partial Mayo Score</measure>
    <time_frame>52 weeks</time_frame>
    <description>For UC patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission status according to Harvey-Bradshaw index</measure>
    <time_frame>52 weeks</time_frame>
    <description>For CD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity according to Harvey-Bradshaw index</measure>
    <time_frame>52 weeks</time_frame>
    <description>For CD patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission status according to PASI</measure>
    <time_frame>52 weeks</time_frame>
    <description>For psoriatic patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease activity according to PASI</measure>
    <time_frame>52 weeks</time_frame>
    <description>For psoriatic patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>RAND SF-36</measure>
    <time_frame>52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Modified Health Assessment Questionnaire (MHAQ)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Only RA, SpA and PsA patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory Bowel Disease Questionnaire (IBDQ)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Only UC and CD patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Only Ps patients</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D</measure>
    <time_frame>52 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>RAID</measure>
    <time_frame>52 weeks</time_frame>
    <description>Only RA patients</description>
  </other_outcome>
  <other_outcome>
    <measure>PsAID</measure>
    <time_frame>52 weeks</time_frame>
    <description>Only PsA patients</description>
  </other_outcome>
  <other_outcome>
    <measure>WPAI:GH</measure>
    <time_frame>52 weeks</time_frame>
    <description>Work Productivity and Activity Impairment Questionnaire: General health</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety and tolerability: AEs, laboratory parameters</measure>
    <time_frame>through study completion, an average of 52 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">482</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Spondyloarthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn's Disease</condition>
  <condition>Psoriasis Chronic</condition>
  <arm_group>
    <arm_group_label>CT-P13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusions of biosimilar infliximab (Remsima) with same dose and frequency as pre-inclusion treatment with innovator infliximab (Remicade)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continued infusions of innovator infliximab (Remicade) with same dose and frequency as prior to inclusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Innovator infliximab</intervention_name>
    <arm_group_label>INX</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biosimilar infliximab</intervention_name>
    <arm_group_label>CT-P13</arm_group_label>
    <other_name>Remsima</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A clinical diagnosis of either rheumatoid arthritis, spondyloarthritis, psoriatic
             arthritis, ulcerative colitis, Crohn's disease or chronic plaque psoriasis

          2. Male or non-pregnant, non-nursing female

          3. &gt;18 years of age at screening

          4. Stable treatment with innovator infliximab (Remicade) during the last 6 months

          5. Subject capable of understanding and signing an informed consent form

          6. Provision of written informed consent

        Exclusion Criteria:

          1. Major co-morbidities, such as severe malignancies, severe diabetic mellitus, severe
             infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class 3
             or 4) and/or severe respiratory diseases

          2. Change of major co-medication during the last 2 months prior to randomization:

             RA, SpA and PsA: Initiation of systemic corticosteroids or synthetic DMARDs or other
             medication which according to the investigator would interfere with the stability of
             the disease.

             UC and CD: Initiation of systemic corticosteroids or an immunosuppressant or other
             medication which according to the investigator would interfere with the stability of
             the disease Psoriasis: Initiation of synthetic DMARDs or other medication which
             according to the investigator would interfere with the stability of the disease

          3. Inadequate birth control, pregnancy, and/or breastfeeding

          4. Psychiatric or mental disorders, alcohol abuse or other substance abuse, language
             barriers or other factors which makes adherence to the study protocol impossible

          5. Change in treatment with innovator infliximab (Remicade) during the last 6 months due
             to disease related factors, not including dose/frequency adjustments due to drug
             concentration measurements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tore K. Kvien, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diakonhjemmet Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sørlandet Sykehus HF</name>
      <address>
        <city>Arendal</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssjukehus Hf</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordlandssykehuset</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Innlandet</name>
      <address>
        <city>Elverum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Østfold HF</name>
      <address>
        <city>Fredrikstad</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helse Førde Hf</name>
      <address>
        <city>Førde</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bærum Sykehus</name>
      <address>
        <city>Gjettum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Innlandet</name>
      <address>
        <city>Gjøvik</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Innlandet</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haugesund Sanitetsforenings Revmatismesykehus</name>
      <address>
        <city>Haugesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helse Fonna HF</name>
      <address>
        <city>Haugesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sørlandet Sykehus HF</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helse Nord-Trøndelag</name>
      <address>
        <city>Levanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatismesykehuset Lillehammer</name>
      <address>
        <city>Lillehammer</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Innlandet</name>
      <address>
        <city>Lillehammer</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akershus Universitetssykehus</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helgelandssykehuset</name>
      <address>
        <city>Mo i Rana</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Diakonhjemmet Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0319</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonhjemmet Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus, Ullevål</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martina Hansens Hospital</name>
      <address>
        <city>Sandvika</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Betanien Hospital</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Telemark HF</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset i Nord-Norge</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital HF</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehuset Vestfold</name>
      <address>
        <city>Tønsberg</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ålesund Sjukehus, Helse Møre og Romsdal HF</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2014</study_first_submitted>
  <study_first_submitted_qc>May 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diakonhjemmet Hospital</investigator_affiliation>
    <investigator_full_name>Tore K Kvien</investigator_full_name>
    <investigator_title>Prof. Dr. Med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

